Priscilla Lynch
Published: Monday, September 16, 2019

AVEDRO showcased early data on its novel Boost Epi-On cross-linking (CXL) technology for the treatment of keratoconus during an educational session at the 37th Congress of the ESCRS yesterday.
Presentations highlighted the positive early clinical experiences of several clinicians from different countries who have evaluated Boost Epi-On CXL, a non-invasive corneal CXL procedure that does not require removal of the epithelium.
The latest-generation technology addresses the limitations of prior epi-on procedures through the addition of supplemental oxygen. This drives oxygen diffusion across the epithelium to enhance CXL, better stabilising and strengthening the cornea and ultimately halting or slowing keratoconus progression, yesterday’s educational session heard.
The procedure is thus easier, with less postoperative ocular discomfort and a faster recovery time. It is also safer with less risk of complications and preserves corneal thickness as well as improving visual acuity, speakers said.
Speaking to EuroTimes, Avedro CEO Reza Zadno PhD noted that keratoconus is a disease that particularly impacts young people, “and treating and halting its progression leads to a major quality of life improvement for these patients”.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
Read more...
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Read more...
ESCRS Today 2025: All Eyes on Innovation
Watching out for obstacles and opportunities
Read more...
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Read more...
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Read more...
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Read more...
Supplement: ESCRS Clinical Trends Series: Presbyopia
Read more...
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Read more...
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Read more...
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.
Read more...